Heart Failure Market Report (2022 to 2030) – Tenax Therapeutics, Novartis Ag, Bayer Ag, Bristol-Myers Squibb, Eli Lilly And Company

Pune, Jan. 09, 2023 (GLOBE NEWSWIRE) — According to a new market research report titled, “Heart Failure Market by Type (Acute Heart Failure and Chronic Heart Failure) and by Therapeutic Drugs (Cardiac Glycosides, Sympathomimetic Agents, Phosphodiesterase III inhibitors, Diuretics, Aldosterone Antagonist, Vasodilators, and Beta-Blockers) – Global Outlook & Forecast 2022-2030″ published by Growth Plus Reports, the Heart Failure Market is expected to grow at a CAGR of 2.9% from 2021 to reach US$ 9.31 billion by 2030.

Download PDF Brochure of Heart Failure Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at:


Growth Drivers

One of the main factors propelling the growth of the heart failure market is the rising prevalence of heart failure caused by an unhealthy lifestyle in the expanding population. The ageing population, which has a higher risk of developing heart disease and other chronic illnesses like diabetes, also raises the likelihood of organ failure, which boosts the heart failure market’s income. The heart failure market is experiencing revenue growth thanks to technological developments in the treatment of heart failure and an increase in research and drug development for the condition.

The global market has been analyzed from three perspectives: type, therapeutic drugs, and region

Excerpts from ‘By Therapeutic Drugs Segmentation’

Based on therapeutic drugs, the global heart failure market is divided into:

  • Cardiac Glycosides
  • Sympathomimetic Agents
  • Phosphodiesterase Iii Inhibitors
  • Diuretics
  • Aldosterone Antagonists
  • Vasodilators
  • Beta-Blockers

The most popular heart failure medication is a beta-blocker. It lowers blood pressure by causing the heart rate to slow down. As a result, the beta-blocker market segment dominates the overall heart failure market. Whereas the diuretic segment being the first line of treatment remains the mature shareholder of the global heart failure market.

Excerpts from ‘By Region Segmentation’

Based on region, the global heart failure market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • The Rest Of The World.

Over the projected period, the market for heart failure in Asia Pacific is anticipated to develop at the quickest rate. Other factors driving the market’s revenue growth in the area include an increase in the number of heart failure patients, government activities to raise public awareness, and a rise in treatment demand. Another aspect that is anticipated to have a beneficial effect on the future revenue growth of the heart failure market is the existence of a sizable population.

Excerpts from ‘Competitive Landscape’

Some of the prominent players operating in the global heart failure market are:

  • Jarvik Heart, Inc.
  • Boehringer Ingelheim International Gmbh
  • Otsuka Pharmaceutical Co., Ltd.
  • Tenax Therapeutics
  • Eli Lilly And Company
  • Novartis Ag
  • Bayer Ag
  • Astrazeneca
  • Amgen Inc.
  • Bristol-Myers Squibb

Browse Detailed Summary of Research Report with TOC:

Table of Content

    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Acute Heart Failure
    2. Chronic Heart Failure
    1. Cardiac Glycosides
    2. Sympathomimetic Agents
    3. Phosphodiesterase III inhibitors
    4. Diuretics
    5. Aldosterone Antagonist
    6. Vasodilators
    7. Beta – Blockers
    8. Others

Scope of the Report:

Report Attribute Details
Market size value in 2021 US$ 7.2 billion
Revenue forecast in 2030 US$ 9.31 billion
Growth Rate CAGR of 2.9% from 2022 to 2030
Base year for estimation 2021
Forecast period 2022-2030
Segments covered type, therapeutic drugs, and region
Regional scope North America, Europe, Asia Pacific, and the Rest of the World (ROW)


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market


  • Distributor Landscape Assessment
  • Pipeline Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Directly Purchase Premium Copy of Heart Failure Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=WHuocJKe4tQgoVEJ1wkPm2mDhYiHgdXWIqpAgXgp&report_id=8033&license=Single

About Us        

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +91 96545 76783 Web: https://growthplusreports.com/ 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaChron.com takes no editorial responsibility for the same.